Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.

Advertisement

Related Content

Array Withdraws Binimetinib's US Filing On Heels Of Late-Cycle Meeting With FDA
Biosimilar Bummer: FDA Postpones Celltrion Infliximab Advisory Committee
Cell Therapeutics’ Tosedostat Gets Back On Track
Cell Therapeutics’ Tosedostat Gets Back On Track
Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration
Eisai’s Dacogen Final Results On Overall Survival Get Preliminary Test At Advisory Committee
Amgen’s Xgeva For Castration-Resistant Prostate Cancer Faces Panel Review Without Overall Survival Advantage
Cell Therapeutics' Dual Strategy On Pixuvri Will Be Tested At Advisory Committee
CTI's Pixuvri Strategy After FDA Rejection: Pursue Expanded Access, Start Combination Trial
Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel